Article: Idenix: valopicitabine Ph IIb enrollment ends.(Idenix Pharmaceuticals Inc.)(Brief Article)

Article: Galapagos in discovery collaboration with Idenix.(Idenix ...
Pharma Marketletter;  November 28, 2005 ;     609 words ...Belgium-headquartered Galapagos NV says that it has entered into a collaboration with US firm Idenix Pharmaceuticals on selected hepatitis and HIV infectious disease programs. Under the terms of the deal, Galapagos' service division, BioFocus ...

Article: Novirio becomes Idenix Pharmaceuticals, ...
Virus Weekly;  July 9, 2002 ;     475 words ... ... 2002 JUL 9 - (NewsRx.com & NewsRx.net) -- Novirio Pharmaceuticals, Ltd., has changed its name to Idenix Pharmaceuticals, Inc. The new name, Idenix, is intended to reflect the application of its drug discovery expertise and development ...

Article: Inednix Pharma sales decline.(Idenix ...
Pharma Marketletter;  May 2, 2005 ;     580 words ...Idenix Pharmaceuticals, a US biopharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of human ...

Article: Idenix prices $150M offering.(Idenix ...
Pharma Marketletter;  October 31, 2005 ;     568 words ...US firm Idenix Pharmaceuticals has announced the pricing at $20.61 per share of a public offering of 8,220,527 shares of its common stock. Of such shares ...

Article: New data for Idenix' telbivudine.(Idenix ...
Pharma Marketletter;  April 26, 2004 ;     700+ words ...Promising one-year data from a Phase IIb trial of Idenix Pharmaceuticals' antiviral telbivudine were reported at the annual meeting of the European Association for the Study of the Liver, held in Berlin ...

Article: Good Ph III for Idenix/Novartis' telbivudine.(Idenix ...
Pharma Marketletter;  August 8, 2005 ;     700+ words ...Swiss drug major Novartis and US firm Idenix Pharmaceuticals say that the Phase III GLOBE registration trial for telbivudine successfully reached its primary, composite efficacy of therapeutic ...

Article: Idenix' hep B drug superior to lamivudine.(Idenix ...
Pharma Marketletter;  November 21, 2005 ;     700+ words ... ... among others, by Indian drugmaker Ranbaxy, after one year. The drug, is being co-developed by USA-based Idenix Pharmaceuticals and Novartis Pharma AG, and is a specific and selective, oral once-daily nucleoside analog designed to ...